Table 4.

Patient and disease characteristics and univariate analysis

Variable	Overall survival				Failure-free survival
	No. of patients	No. of deaths	5-y overall survival, %	Wilcoxon P	No. of patients	No. of deaths	5-y failure-free survival, %	Wilcoxon P
Age, y				< .001				< .001
Less than 45	109	13	90 ± 3		108	19	84 ± 4
45 or more	36	18	62 ± 8		36	21	55 ± 8
Sex				.24				.40
Male	74	20	82 ± 5		73	23	73 ± 5
Female	71	11	85 ± 4		71	17	80 ± 5
Stage				.04				.11
I, II	83	13	88 ± 4		83	20	81 ± 4
III, IV	61	18	76 ± 6		60	20	69 ± 6
IPS				.002				.003
2 or below	104	17	83 ± 3		103	24	82 ± 4
More than 2	35	13	67 ± 8		35	15	60 ± 8
Bulky disease				.65				.79
No	101	24	81 ± 4		100	30	76 ± 4
Yes	37	7	86 ± 6		37	10	74 ± 8
HGAL				.01				.05
Negative	37	13	70 ± 8		37	15	70 ± 8
Positive	108	18	87 ± 3		107	25	79 ± 4
B symptoms*				.48				.14
No	73	12	87 ± 4		72	16	85 ± 4
Yes	46	10	84 ± 6		46	15	69 ± 7
No. of sites*				.79				.25
1-3	72	13	87 ± 4		72	17	83 ± 4
More than 3	44	9	82 ± 6		43	13	72 ± 7

^*Restricted to patients with stage I or II disease.